Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320670 | 1.00 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16320897 | 1.00 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1260626 | 1.00 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL31165203 | 1.00 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6156168 | 0.90 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL8437306 | 0.90 | CYP2D6 (0.45) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1172339 | 0.83 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1172340 | 0.83 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6154559 | 0.82 | CYP2D6 (0.50) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6872772 | 0.81 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114410599-B | Carbonyl reductase mutant and application thereof in preparation of rosuvastatin chiral intermediate | 浙江工业大学 | 2023-08-18 | — | — | CN | claimed |
| CN-114875081-A | Green industrial production method of rosuvastatin key intermediate | 湖北迅达药业股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114410599-A | Carbonyl reductase mutant and application thereof in preparing rosuvastatin chiral intermediate | 浙江工业大学 | 2022-04-29 | — | — | CN | claimed |
| CN-107653238-B | Carbonyl reductase gene engineering bacterium immobilized cell and application thereof | 浙江工业大学 | 2021-05-11 | — | — | CN | claimed |
| CN-108486075-B | Recombinant carbonyl reductase mutant, gene, engineering bacterium and application thereof | 浙江工业大学 | 2020-11-13 | — | — | CN | claimed |
| CN-108048438-B | Halohydrin dehalogenase mutant and application thereof | 浙江宏元药业股份有限公司 | 2020-08-18 | — | — | CN | claimed |
| EP-3134519-B1 | KETOREDUCTASES | C LECTA GMBH (DE) | 2018-06-06 | — | — | EP | claimed |
| CN-117089533-A | Recombinant carbonyl reductase, mutant, coding gene and application thereof | 浙江工业大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-114410599-B | Carbonyl reductase mutant and application thereof in preparation of rosuvastatin chiral intermediate | 浙江工业大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-114875081-A | Green industrial production method of rosuvastatin key intermediate | 湖北迅达药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114874181-A | Preparation method of rosuvastatin chiral side chain intermediate | 湖北迅达药业股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114410599-A | Carbonyl reductase mutant and application thereof in preparing rosuvastatin chiral intermediate | 浙江工业大学 | 2022-04-29 | — | — | CN | disclosed |
| CN-114181188-A | Non-solvation synthesis method of atorvastatin calcium intermediate | 江苏阿尔法药业股份有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-1619191-A2 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl] acetic acid derivatives | KANEKA CORPORATION (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-6903225-B2 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4-yl]acetic acid derivatives | KANEKA CORPORATION (JP) | 2005-06-07 | — | — | US | disclosed |
| EP-1024139-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2-(6-(HYDROXYMETHYL)-1,3-DIOXAN-4-YL) ACETIC ACID DERIVATIVES | KANEKA CORP (JP) | 2004-05-12 | — | — | EP | disclosed |
| EP-1394157-A2 | Process for the preparation of 3,5-dihydroxy substituted esters as intermediates for producing optically active 2-(6-(hydroxymethyl)-1,3-dioxan-4-yl) acetic acid dervatives | KANEKA CORPORATION (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20030040634-A1 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4yl]acetic acid derivatives | KANEKA CORPORATION (JP) | 2003-02-27 | — | — | US | disclosed |
| US-6472544-B1 | REACTING ACETIC ACID DERIVATIVE WITH AN ENOLATE, REDUCING WITH A MICROORGANISM, ACETALIZING IN PRESENCE OF ACID CATALYST THEN ALKALINE SAPONIFICATION; NO SPECIAL EQUIPMENT OR SUPER LOW TEMPERATURE REQUIRED; INEXPENSIVE STARTING MATERIALS | KANEKA CORPORATION (JP) | 2002-10-29 | — | — | US | disclosed |
| EP-1024139-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2- 6-(HYDROXYMETHYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2000-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040634-A1 | Process for producing optically active 2-[6-(hydroxymethyl)-1,3-dioxan-4yl]acetic acid derivatives | HAAO, APEH, AADAC | CYP2D6 98/4885HDAC3 529/4885HDAC1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.